Sanofi Halts Multaq Trial Early Due To Cardiac Events
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.